Altimmune, Inc. (ALT) income statement
ALTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$1.39−0.14 (-9.15%)
Close on Nov 18, 2026Market cap $270.38MP/E –Yield –
Altimmune, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- -244451.2%
- Net margin
- -223804.9%
- Return on equity, FY2025
- -50.6%
Financial strength
- Current ratio
- 26.78
- Debt to equity
- 0.07
- Debt to assets
- 6.6%
- Cash to current liabilities
- 504.0%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.57
- Dividend yield
- –
See a number that looks wrong?